Isenbrandt Amandine, Morissette Marc, Bourque Mélanie, Lamontagne-Proulx Jérôme, Coulombe Katherine, Soulet Denis, Di Paolo Thérèse
Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, (Québec) G1V 0A6, Canada.
Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada.
Neuropharmacology. 2021 Dec 15;201:108784. doi: 10.1016/j.neuropharm.2021.108784. Epub 2021 Sep 20.
The main neuropathological feature of Parkinson's disease (PD) is degeneration of dopamine (DA) neurons in the substantia nigra (SN); PD prevalence is higher in men, suggesting a role of sex hormones in neuroprotection. This study sought the effects of sex hormones in the brain in a mouse model of PD and modulation of steroid metabolism/synthesis with the 5α-reductase inhibitor dutasteride shown to protect 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) male mice. Male and female mice were gonadectomized (GDX) or SHAM operated. They were treated with vehicle or dutasteride (5 mg/kg) for 10 days and administered a low dose of MPTP (5.5 mg/kg) or saline on the 5th day to model early PD; brains were collected thereafter. Striatal measures of the active metabolite 1-methyl-4-phenylpyridinium (MPP) contents showed no difference supporting an effect of the experimental conditions investigated. In SHAM MPTP male mice loss of striatal DA and metabolites, DA transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) specific binding in the striatum and SN was prevented by dutasteride treatment; these changes were inversely correlated with glial fibrillary acidic protein (GFAP, an astrogliosis marker) levels. In SHAM female mice MPTP treatment had little or no effect on striatal and SN DA markers and GFAP levels whereas GDX male and female mice showed a similar loss of striatal DA markers and increase of GFAP. No effect of dutasteride treatment was observed in GDX male and female mice. In conclusion, sex differences in mice MPTP toxicity and response to dutasteride were observed that were lost upon gonadectomy implicating neuroinflammation.
帕金森病(PD)的主要神经病理学特征是黑质(SN)中多巴胺(DA)神经元的变性;PD在男性中的患病率更高,这表明性激素在神经保护中发挥作用。本研究在PD小鼠模型中探寻性激素在大脑中的作用,以及用5α-还原酶抑制剂度他雄胺调节类固醇代谢/合成的作用,度他雄胺已被证明可保护1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的雄性小鼠。对雄性和雌性小鼠进行去势(GDX)或假手术。它们用溶剂或度他雄胺(5mg/kg)处理10天,并在第5天给予低剂量的MPTP(5.5mg/kg)或生理盐水以模拟早期PD;此后收集大脑。纹状体中活性代谢物1-甲基-4-苯基吡啶鎓(MPP)含量的测量结果显示无差异,支持所研究实验条件的作用。在假手术的MPTP雄性小鼠中,度他雄胺治疗可防止纹状体DA和代谢物、DA转运体(DAT)以及纹状体和黑质中囊泡单胺转运体2(VMAT2)特异性结合的丧失;这些变化与胶质纤维酸性蛋白(GFAP,一种星形胶质细胞增生标志物)水平呈负相关。在假手术的雌性小鼠中,MPTP处理对纹状体和黑质DA标志物及GFAP水平几乎没有影响,而去势的雄性和雌性小鼠显示出类似的纹状体DA标志物丧失和GFAP增加。在去势的雄性和雌性小鼠中未观察到度他雄胺治疗的效果。总之,观察到小鼠MPTP毒性和对度他雄胺反应的性别差异,而去势后这些差异消失,这表明与神经炎症有关。